Sentinel Lymph Node Biopsy Market Size & Growth Report to 2030

The global sentinel lymph node biopsy market size was valued at around USD 0.5 billion in 2022 and anticipated to register a significant CAGR of around 5% during the forecast period from 2023 to 2030. The rising cancer rates, notably breast cancer and melanoma, necessitate accurate staging and treatment planning. SLNB’s minimally invasive nature reduces complications, while its heightened accuracy in detecting lymph node involvement enhances treatment decisions. Technological advancements, like improved imaging and detection techniques, bolster SLNB’s precision. Public awareness campaigns promote early cancer detection, driving demand for SLNB’s timely interventions. As healthcare trends shift towards outpatient care and personalized medicine, SLNB’s outpatient feasibility and contribution to tailored treatments make it more appealing. Regulatory approvals instill confidence, and collaborations drive innovation, resulting in increased accessibility to SLNB procedures worldwide.

Market Snapshot:

To know more about the research study, request sample papers

Market Drivers:

Rising Cancer Incidence: The global incidence of cancer, particularly breast cancer and melanoma, has been on the rise. As the number of individuals diagnosed with these types of cancers increases, there is a growing need for accurate and efficient diagnostic and staging techniques. SLNB serves as a valuable tool in providing precise information about the spread of cancer to lymph nodes.

Minimally Invasive Procedures: Traditional lymph node dissection, involving the removal of multiple nodes, can be invasive and result in potential complications such as lymphedema. SLNB offers a minimally invasive alternative, reducing the extent of surgical intervention and associated risks. Patients and healthcare professionals increasingly prefer procedures that minimize trauma and promote faster recovery.

Improved Staging Accuracy: Accurate staging is critical for determining the appropriate treatment strategy for cancer patients. SLNB has demonstrated higher accuracy in detecting lymph node involvement compared to manual palpation. This precision helps oncologists make informed decisions about surgery, radiation, and chemotherapy.

Customized Treatment Plans: SLNB results provide crucial information that guides personalized treatment plans. Patients with negative SLNB results can potentially avoid unnecessary extensive lymph node dissections, which can lead to improved quality of life by reducing the risk of complications and side effects.

Advancements in Imaging and Detection Techniques: Technological advancements have greatly enhanced the accuracy and efficiency of SLNB procedures. Gamma probes and fluorescence imaging systems have evolved to provide real-time guidance, making it easier for surgeons to identify and remove sentinel lymph nodes with precision.

Awareness and Early Detection: Public awareness campaigns and education about the importance of early cancer detection have contributed to an increased willingness among individuals to undergo screening and diagnostic procedures. SLNB plays a crucial role in detecting cancer at an early stage, facilitating timely interventions and better treatment outcomes.

Shift toward Outpatient Procedures: SLNB is often performed as an outpatient procedure, allowing patients to return home on the same day. This not only reduces the financial burden on patients but also eases the strain on healthcare facilities by freeing up hospital beds and resources.

Growing Emphasis on Personalized Medicine: Modern oncology is moving towards personalized treatment approaches. SLNB results provide specific information about the characteristics of a patient’s cancer, allowing oncologists to tailor therapies that target the unique features of the disease.

Market Insights:

Market Analysis by Product Type:

The global sentinel lymph node biopsy market is bifurcated into product type, indication, end-user, and geography. on the basis of product type, the gamma probe segment is accounted to hold a significant revenue share in the benchmark year 2022. Gamma probes hold a pivotal role in the SLNB procedure, serving as essential tools for detecting radioactive signals emitted by a radioactive tracer injected near the tumor site. This technological innovation empowers surgeons to accurately locate and subsequently remove the sentinel lymph nodes with a high degree of precision. The utilization of gamma probes significantly enhances the reliability of SLNB, reducing the potential for false-negative results and minimizing unnecessary lymph node removal. The real-time visualization of lymphatic drainage pathways through radioactivity aids surgeons in precisely identifying sentinel nodes, which in turn is vital for accurately staging cancers. Ongoing advancements in gamma probe technology have reinforced their dominance in the SLNB market. Improved sensitivity, streamlined data visualization, and ergonomic design have collectively elevated the efficiency and effectiveness of gamma probes. As surgeons heavily rely on gamma probes to guide them during SLNB procedures, the accuracy of these devices directly influences patient outcomes and subsequent treatment decisions.

Breast Localization Wire: These wires are used to locate and mark the location of abnormal tissue or lesions in the breast prior to surgery. They help guide the surgeon to the target area for precise tissue removal, aiding in accurate diagnoses and treatment.

Tissue Marker: Tissue markers are small devices or substances used to mark specific locations within the body, often where biopsies or surgical procedures have been performed. In SLNB, tissue markers may be used to indicate the location of the sentinel lymph nodes for ease of identification during surgery.

Gamma Probe: Gamma probes are specialized handheld devices that detect radioactive signals emitted by a radioactive tracer injected near the tumor site. These probes help surgeons locate and remove the sentinel lymph nodes by following the path of radioactive material, thereby improving accuracy.

Drainage Catheter: Drainage catheters are inserted into the surgical site to drain excess fluid or blood that may accumulate after surgery. In SLNB procedures, they can be utilized to manage drainage and reduce post-operative complications.

Others: This category encompasses various additional products that contribute to the SLNB procedure. This could include items like surgical instruments, imaging technologies, consumables, and other accessories that support the accurate and successful execution of SLNB.

Market Analysis by End-User:

On the basis of end-user, the global sentinel lymph node biopsy market is further segmented into hospitals & clinics, diagnostic centers, and others. the hospitals & clinics segment dominated the global market in the benchmark year 2022. Hospitals and clinics are often the primary choice for SLNB procedures due to their comprehensive medical infrastructure, multidisciplinary teams, and advanced surgical facilities. These settings provide a wide range of medical services, including cancer diagnosis and treatment. Surgeons and oncologists in hospital departments and specialized clinics are well-equipped to perform SLNB procedures as part of cancer staging and treatment plans. Hospitals offer the advantage of handling more complex cases and having a broader spectrum of medical specialties available for consultation, enhancing the overall patient care experience.

Hospitals & Clinics: Hospitals and clinics collectively represent a significant portion of the SLNB market. These facilities provide a comprehensive range of medical services, making them well-equipped to perform SLNB procedures. Hospitals offer specialized surgical departments where SLNB can be conducted as part of cancer treatment plans. Specialty clinics, focused on oncology or surgical interventions, offer tailored expertise and streamlined care. The diverse capabilities of hospitals and clinics ensure that SLNB procedures can be efficiently carried out in various medical contexts.

Diagnostic Centers: Diagnostic centers play a critical role in the SLNB market by providing accurate and timely diagnostic imaging services. These centers often use imaging technologies such as ultrasound, MRI, and CT scans to assist in locating sentinel lymph nodes and assessing their status. Diagnostic centers collaborate closely with surgical facilities to provide the necessary preoperative imaging for successful SLNB procedures. Their role in precise preoperative planning contributes to the overall effectiveness of SLNB.

Others: The “Others” category encompasses various healthcare settings that contribute to the SLNB market but might not fit neatly into the hospital, clinic, or diagnostic center classification. This could include academic medical centers, research institutions, and outpatient surgical facilities. These settings might offer unique advantages such as advanced research capabilities, multidisciplinary collaboration, or specialized expertise in certain cancer types.

The sentinel lymph node biopsy market research report presents the analysis of each segment from 2020 to 2030 considering 2022 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2023 to 2030.

Historical & Forecast Period

• 2020-21 – Historical Year
• 2022 – Base Year
• 2023-2030 – Forecast Period

Market Segmentation:

By Product Type:

• Breast Localization Wire
• Tissue Marker
• Gamma Probe
• Drainage Catheter
• Others

By Indication:

• Breast Cancer
• Melanoma
• Others

By End-User:

• Hospitals & Clinics
• Diagnostic Centers
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis:

Geographically, North America dominated the global sentinel lymph node biopsy market and expected to hold the largest revenue share over the forecast period. This region’s dominance can be attributed to several factors. North America, especially the United States, boasts advanced healthcare systems, robust research and development activities, and a high prevalence of breast cancer and melanoma cases. These factors drive the demand for accurate cancer diagnostics and staging techniques like SLNB. Moreover, strong collaborations between academic institutions, research centers, and healthcare facilities facilitate the dissemination of cutting-edge technologies and techniques, contributing to the region’s dominance in the market.

The adoption of SLNB in North America is further supported by well-established regulatory frameworks and guidelines that ensure the safety and efficacy of medical procedures. The region’s economic affluence allows for investments in state-of-the-art medical equipment, training programs, and comprehensive cancer care centers. Patients’ access to healthcare information, early detection campaigns, and awareness initiatives also contribute to the prominence of North America in the SLNB market.

Competitive Analysis:

Some of the major market players operating in the global sentinel lymph node biopsy market are Becton, Dickinson and Company, Cook Medical, Medtronic, Argon Medical Devices, and Invivo Corporation. These companies are the leading players in the market due to their strong product portfolio, extensive distribution network, and innovative research and development capabilities. They are constantly investing in new technologies and products to meet the growing demand for sentinel lymph node biopsy. Companies are exploring markets with expansion and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Recent Developments:

• In May 2022, KUBTEC® acquired Wprobe technology from Oncovision’s firm. This technology is a gold standard in radio-guided surgery and involved a range of wireless gamma probes for sentinel lymph node identification. This acquisition will help KUBTEC® to strengthen its position in the sentinel lymph node biopsy market.
• In June 2022, Becton, Dickinson and Company launched its new gamma probe, the Tri-Probe. The Tri-Probe is a handheld device that can detect three different radioactive isotopes, making it more versatile than traditional gamma probes. This launch is expected to help Becton, Dickinson and Company to gain a competitive advantage in the sentinel lymph node biopsy market.
• In July 2022, Cook Medical launched its new breast localization wire, the ProGuide Wire. The ProGuide Wire is a thin, flexible wire that is inserted into the breast to help guide the surgeon to the sentinel lymph node. This launch is expected to help Cook Medical to expand its product portfolio and meet the growing demand for breast localization wires in the sentinel lymph node biopsy market.
• In October 2021, Southern Scientific collaborated with Helgeson. Helgeson is a manufacturer of several detectors, area monitors, and equipment control with more than 30 years of experience in the nuclear industry. This collaboration will help Southern Scientific to expand its product portfolio and offer a wider range of gamma probes for sentinel lymph node biopsy.

Key Companies:

• Becton, Dickinson and Company
• Cook Medical
• Medtronic
• Argon Medical Devices
• Invivo Corporation
• Medline Industries, Inc.
• Cardinal Health
• Merit Medical Systems, Inc.
• Southern Scientific
• KUBTEC®

Key Questions Answered by Sentinel Lymph Node Biopsy Market Report

• Global sentinel lymph node biopsy market forecasts from 2023-2030
• Regional market forecasts from 2023-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2023-2030 covering 15 major countries from the regions as mentioned above
• Sentinel lymph node biopsy submarket forecasts from 2023-2030 covering the market by product type, indication, end-user, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level sentinel lymph node biopsy markets from 2023-2030
• Competitive Landscape and market positioning of top 10 players operating in the market